Aims: Tumour budding in colorectal cancer (CRC) is a recognized prognostic parameter. The aim of this study was to address the use of cytokeratin immunostaining for the visualization and scoring of tumour buds. Methods and results: Ten hotspots (0.238 mm 2 ) of peritumoural budding (PTB) and intratumoural budding (ITB) were evaluated in surgical resections from 215 patients. The budding counts in the 10 densest regions anywhere in the tumour were combined into an overall tumour budding (OTB) score. The PTB, ITB and OTB hotspot with the maximum budding count was then evaluated. Finally, continuous and cut-off values of 10 buds per high-power field (HPF) (PTB 10HPF ), five buds per HPF (ITB 10HPF ) and eight buds per HPF (OTB 10HPF ) were used to categorize budding counts into low-grade and high-grade scores. All budding scores were highly correlated. PTB and ITB counts were associated with many clinicopathological features, including tumour stage, lymph node and distant metastasis, venous and lymphovascular invasion, and disease-free survival (DFS) (all P < 0.05). Analyses of OTB counts recapitulated these associations, including a lower DFS with a greater number of tumour buds (P = 0.0309; hazard ratio 1.0332, 95% confidence interval 1.003-1.062). One OTB hotspot performed similarly to 10 OTB hotspots in terms of relationship with outcome. These statistical significances were largely lost when cut-offs were applied to PTB, ITB or OTB counts. Conclusions: An OTB count in a single hotspot on cytokeratin-stained CRC tissue sections is a fast and reliable prognostic scoring system for the assessment of tumour budding. This approach should be considered in future studies.
Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer
Aims: Tumour budding in colorectal cancer (CRC) is a recognized prognostic parameter. The aim of this study was to address the use of cytokeratin immunostaining for the visualization and scoring of tumour buds. Methods and results: Ten hotspots (0.238 mm 2 ) of peritumoural budding (PTB) and intratumoural budding (ITB) were evaluated in surgical resections from 215 patients. The budding counts in the 10 densest regions anywhere in the tumour were combined into an overall tumour budding (OTB) score. The PTB, ITB and OTB hotspot with the maximum budding count was then evaluated. Finally, continuous and cut-off values of 10 buds per high-power field (HPF) (PTB 10HPF ), five buds per HPF (ITB 10HPF ) and eight buds per HPF (OTB 10HPF ) were used to categorize budding counts into low-grade and high-grade scores. All budding scores were highly correlated. PTB and
Introduction
Single cancer cell invasion or collective migration of small tumour clusters in the stroma of colorectal cancer (CRC) is referred to as tumour budding. 1 The presence of tumour buds at the invasion front [peritumoural budding (PTB)] and in the tumour centre [intratumoural budding (ITB)] is linked to an aggressive tumour phenotype with adverse clinicopathological features and poorer survival of CRC patients. [2] [3] [4] [5] [6] Quantification of tumour buds has great potential for clinical management. First, enumeration of tumour buds may improve the risk stratification of patients with endoscopically resected CRC, and can aid in making the decision on whether to perform colorectal surgery. [6] [7] [8] [9] [10] Second, assessment of tumour budding may allow the identification of high-risk stage II CRC patients for intensified follow-up and adjuvant therapy trials. 2, 4, 11 Third, the detection of tumour buds in preoperative biopsies may indicate an increased risk of nodal metastases and resistance to neoadjuvant therapy in rectal cancer patients. 12, 13 Recently, an international panel of experts recommended guidelines for the assessment of tumour budding and outlined several areas that would benefit from a higher level of evidence in future studies.
14 In particular, the role of cytokeratin (CK) staining, its corresponding scoring system (counts versus lowgrade/high-grade categories and number of fields) and the location within the tumour (ITB or PTB) were outlined as critical areas for further pursuit.
In this study, we performed a comprehensive methodological assessment of tumour budding on CKstained sections in order to answer questions regarding: the optimal tumour location for scoring, the use of continuous/categorical scoring approaches, and the number of fields.
Patients and methods
A sample size calculation was performed in order to determine the number of patients for inclusion in this retrospective cohort. With lymph node status as outcome, and high-grade/low-grade budding as predictor, 160 patients of all stages were required to reach 80% power, and an effect size of odds ratio = 2.8. Two-hundred and fifteen non-consecutive primary CRC patients were included. These patients were treated between 2002 and 2011 at the Bern University Hospital, Switzerland. Histopathological haematoxylin and eosin (H&E)-stained slides were re-reviewed (A.L., H.D., and V.H.K.) according to the UICC TNM 7th edition. 15 Patient characteristics are summarized in Table S1 , and include information on gender, age, histological subtype (adenocarcinoma, mucinous, other), tumour location, pathological tumour stage (pT), nodal stage, the presence of distant metastasis as determined by clinical and radiographic examination, data on lymphatic, venous and perineural invasion, tumour grade, resection status, tumour border configuration as a percentage of pushing growth pattern, tumour deposits, and preoperative and postoperative therapy. Microsatellite instability status (MSI) was determined with a panel of three Bethesda markers (BAT25, BAT26, and D2S123), as previously described. 16 Tumours were classified as MSI+ if they had two or more unstable markers and MSI-if all markers were stable. One tumour showing one single unstable marker was not classified. Clinical and survival information was retrieved from patient records. Mean and median follow-up were 44 months and 32 months, respectively (range: 1-142 months). No patients were treated with endoscopic tumour resection or neoadjuvant chemotherapy. Patients were followed up in accordance with the recommendations of the Swiss Society of Gastroenterology for surgically resected colorectal tumours. 17 This includes serial clinical examinations and evaluation of carcinoembryonic antigen serum levels, colonoscopies at 12 months and 48 months, and yearly computed tomography (CT) scans of the thorax and abdomen for patients with pT3/4 disease following resection. For rectal cancer patients, rectal endosonography or pelvic magnetic resonance imaging is performed at 6-monthly intervals for the first 2 years, followed by yearly CT scans of the thorax, abdomen, and pelvis. A lower gastrointestinal endoscopy is performed at 6, 18 and 24 months.
A S S A Y M E T H O D S
Specimens were fixed in 10% neutral buffered formalin. Gross assessment, dissection and sampling was performed in accordance with standard protocols. All diagnostic slides were re-reviewed, and the tumour block with the highest budding grade on standard H&E histology was selected for CK immunohistochemistry (AE1/AE3; Dako M351501-2 mouse monoclonal antibody; Dako Schweiz GmbH, Baar, Switzerland; 1:200; enzyme pretreatment for 5 min, 3,3 0 -diaminobenzidine chromogen) performed on a Leica Bond III instrument (Leica Biosystems, Muttenz, Switzerland). Double staining for CD8 and CK was performed but was not evaluated for this study.
A S S E S S M E N T O F T U M O U R B U D D I N G
Tumour budding was defined as single tumour cells or tumour cell clusters of up to five cells in the tumour stroma of the invasive front (PTB) or within the tumour (ITB), in keeping with previously published definitions. 3, 6, 18 Specifically, tumour budding cells were required to show cytoplasmic positivity and a nucleus on CK staining. To be classified as ITB, tumour buds had to be surrounded by malignant glands on all sides. To be classified as PTB, tumour buds had to be localized in the tumour stroma ahead of the invasive front.
Tumour budding was assessed by one observer (G.R.) trained and supported by a team of expert gastrointestinal pathologists. Slides were first viewed at low power to identify the densest areas of PTB and ITB. Tumour buds were counted in this area in one high-power field (HPF) (Nikon Eclipse 50i, 940 objective, field diameter of 0.55 mm, area of 0.238 mm 2 ; Nikon AG Instruments, Egg, Switzerland), which was labelled as the hotspot of tumour budding (PTB hotspot ; ITB hotspot ). A total of 10 HPFs in each area were evaluated for PTB 10HPF and ITB 10HPF . Overall tumour budding scores were defined as the hotspot with the highest score (OTB hotspot ) and the 10 HPFs with the highest budding counts (OTB 10HPF ). The study design is shown in Figure 1 . All observers were blinded to clinicopathological data.
S T A T I S T I C S
Disease-free survival (DFS) was defined as the time from surgical resection to recurrence or death, whichever occurred first, with recurrence being defined only by the reappearance of the primary CRC. Descriptive statistics were used for all budding counts. Pearson's correlation coefficient was used to determine the strength of the linear relationship (r). The association of tumour budding as a continuous variable with categorical endpoints was analysed with the Wilcoxon rank sum test and with logistic regression. Previously published cut-offs of 10 buds for the PTB 10HPF 19 method and five buds for the ITB 10HPF 20 method were used. For OTB, receiver operating characteristic (ROC)-derived thresholds were investigated, with death as an endpoint. The Kaplan-Meier method was used to represent survival curves, and the logrank test was used to test significant survival time differences. The chi-square test or Fisher's exact test was used where appropriate. Analyses were performed with SPSS (Version 21) and with SAS (Version 9.4; SAS Institute, Cary, NC, USA). P-values of <0.05 were considered to be statistically significant.
E T H I C S A P P R O V A L
The use of patient material was approved by the ethics commission of the canton of Bern (KEK-200/ 14).
Results
Tumour budding was assessed in one hotspot or in 10 hotspots containing the densest regions of tumour buds in three different locations: ITB, PTB, or independently of location with an OTB count ( Figure 2 ).
T O P O G R A P H I C A S S E S S M E N T O F T U M O U R B U D D I N G I N C R C
Descriptive statistics for PTB, ITB and OTB are shown in 
Continuous scores
Tumour budding counts in any location were not correlated with gender, age, resection margin status, or MSI status. Table 3 shows the associations between PTB, ITB and OTB and other clinicopathological features. Tumour budding counts were significantly associated (P < 0.05, all) with more advanced T-stage, nodal metastasis, lymphatic invasion, venous invasion, tumour grade, perineural invasion and infiltrating tumour border configuration, independently of the location of assessment (PTB, ITB or OTB, hotspot or 10 HPFs). DFS times were available for 208 patients, with 38 patients relapsing during clinical follow-up. Significant associations of tumour budding counts with a 
Cut-off scores
In order to determine the impact of cut-off scores on the association of budding with clinicopathological features, we applied a threshold of 10 buds for PTB counts, 19 a threshold of five buds for ITB counts, 20 and newly identified thresholds of 8 and 14 for OTB 10HPF and OTB hotspot . The frequencies of highgrade budding for PTB, ITB and OTB are shown in Table S2 . Table 3 shows loss of associations when budding scores were dichotomized. Only the presence of nodal metastasis and infiltrating tumour border configuration (both P < 0.05) were reliably predicted by classification according to cut-off scores. Inconsistent associations were also identified between highgrade budding cancers and clinical evidence of distant metastasis. Importantly, no associations of tumour budding as assessed by cut-off scores with DFS were identified (PTB 10HPF , P = 0.6681; ITB 10HPF , P = 0.7198; OTB 10HPF , P = 0.7831; PTB hotspot , P = 0.8864; ITB hotspot , P = 0.5243; OTB hotspot , P = 0.4534).
Discussion
The International Tumour Budding Consensus Conference in April 2016 gathered experts from around the world to discuss the issues related to tumour budding 14 . One major area of interest was the use of CK stains for scoring. It was outlined that the evidence supporting the implementation of CK staining was moderate to low, and was an area requiring further work in future studies. We undertook this study to confirm the utility of CK staining for the evaluation of tumour budding.
Evidence from the literature suggests that both PTB in surgical resections and ITB in preoperative biopsies is predictive not only of lymph node and distant metastasis, but also of poorer overall survival and DFS. 3, 6 However, what qualifies as PTB and ITB in resection specimens is not always clear, and the borders between PTB and ITB are often blurred. In a first step, we scored 10 clearly defined regions of PTB and ITB, which were then used to calculate an OTB score to determine the impact of the location of scoring on clinicopathological endpoints. All values of budding were highly correlated with each other. Moreover, we show that the associations identified from PTB and ITB are recapitulated in OTB, suggesting that, as long as the densest region of tumour budding is identified, the location (PTB or ITB) does not actually play a role.
Scoring systems for tumour budding include both subjective and more quantitative methods, and often only a single field of view is considered. 5, 21, 22 Previous studies on PTB have demonstrated that the evaluation of one or 10 hotspots on CK staining produces nearly identical results in terms of interobserver agreement, although with a slight advantage for PTB counted in multiple regions. 23 In this study, we show that the evaluation of a single OTB hotspot performs similarly to the evaluation of 10 OTB regions, suggesting that only one densest region of tumour budding scored anywhere throughout the tumour should be sufficient. Several arbitrary cut-offs ranging from single cells to small clusters of ≤4 or ≤5 have been used for the definition of a single tumour bud (see Mitrovic et al. 3, 18 for critical discussion). A consistent adverse prognostic impact of tumour budding has been observed in studies using either value. 18 However, a systematic comparison is so far lacking in the literature, and needs to be addressed in future investigations.
Another central issue is the use of tumour budding counts or a low-grade/high-grade scoring approach, determined around a cut-off. 3, 6 The distribution of tumour budding counts points to no obvious cut-off that would separate this cohort of patients. Additionally, the ROC curve for tumour budding and lymph node metastasis (or any other endpoint with clinical relevance) presents no evident cut-off point to best discriminate between outcomes. Several more arguments supporting a continuous count of tumour buds can be made, as follows. A larger number of tumour buds can potentially have a clinically relevant meaning-we have previously shown this in the context of ITB in rectal tumour biopsies, with the aim of predicting lymph node and distant metastasis. 20 Tumours with nine or 11 buds cannot be so biologically different that they warrant being placed into low-grade and high-grade categories by use of a cut-off of 10 buds. In this study, we show that the associations of tumour budding with a range of different clinicopathological features, and most importantly with DFS, are only achieved with continuous scores. On the basis of these arguments, we reason that the number of tumour buds on CK staining should be recorded, even if these counts are used in a categorical scoring system in a second step. This study specifically focuses on CK staining for the evaluation of tumour budding cells. We used AE1/AE3 CK staining based on previous studies. 19, 20, 24 AE1/AE3 is a keratin cocktail that detects CK1-6, CK8, CK10, CK14-16 and CK19, but does not detect CK17 or CK18. 25 The choice of a broadspectrum anti-CK is of central importance, as some molecular subgroups of CRC may express a differential cytokine profile. In particular, MSI+ CRC may show loss of CK20 and aberrant expression of CK7. 26 Furthermore, some CRCs with neuroendocrine differentiation may show only a focal or dot-like expression of CK at the invasive front, making careful interpretation mandatory. 27 To conclude, this study demonstrates that an OTB count in a single hotspot on CK-stained CRC tissue sections excels in the assessment of tumour budding. Although further studies are needed to validate these findings, a count of OTB encompasses the positive aspects of PTB and ITB, and will therefore be applicable to both surgical resections and preoperative biopsies.
